Over 800 Million SpikeVax Vaccines Shipped

Massachusetts-based Moderna Inc. today announced it had shipped about 807 million doses of Moderna's COVID-19 SpikeVax vaccine in 2021. These shipments produced approximately $17.5 billion in revenue (unaudited).

About 25% of those SpikeVax vaccine doses were shipped to low- and middle-income countries.

Furthermore, Moderna has signed Advanced Purchase Agreements that could generate approximately $18.5 billion in SpikeVax revenues and approximately $3.5 billion in options, including any potential updated COVID-19 vaccine booster candidates.

"While our COVID-19 vaccine is our first medicine to market, we have made significant progress across our pipeline of 40 development programs and now have 23 mRNA programs in clinical trials," stated Moderna's CEO Stéphane Bancel, in a press release.

Bancel is scheduled to present a Company update and its pipeline of mRNA vaccine development programs on Monday, January 10, 2022, at the 40th Annual J.P. Morgan Healthcare Conference.